Literature DB >> 15289350

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.

Sandeep Batra1, C Patrick Reynolds, Barry J Maurer.   

Abstract

Patients with disseminated Ewing's family of tumors (ESFT) often experience drug-resistant relapse. We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse. We determined the following: (a) 4-HPR cytotoxicity against 12 ESFT cell lines in vitro; (b) whether 4-HPR increased ceramide species (saturated and desaturated ceramides); (c) whether physiological hypoxia (2% O(2)) affected cytotoxicity, mitochondrial membrane potential (DeltaPsi(m)) change, or ceramide species or reactive oxygen species levels; (d) whether cytotoxicity was enhanced by l-threo-dihydrosphingosine (safingol); (e) whether physiological hypoxia increased acid ceramidase (AC) expression; and (f) the effect of the AC inhibitor N-oleoyl-ethanolamine (NOE) on cytotoxicity and ceramide species. Ceramide species were quantified by thin-layer chromatography and scintillography. Cytotoxicity was measured by a fluorescence-based assay using digital imaging microscopy (DIMSCAN). Gene expression profiling was performed by oligonucleotide array analysis. We observed, in 12 cell lines tested in normoxia (20% O(2)), that the mean 4-HPR LC(99) (the drug concentration lethal to 99% of cells) = 6.1 +/- 5.4 microm (range, 1.7-21.8 microm); safingol (1-3 microm) synergistically increased 4-HPR cytotoxicity and reduced the mean 4-HPR LC(99) to 3.2 +/- 1.7 microm (range, 2.0-8.0 microm; combination index < 1). 4-HPR increased ceramide species in the three cell lines tested (up to 9-fold; P < 0.05). Hypoxia (2% O(2)) reduced ceramide species increase, DeltaPsi(m) loss, reactive oxygen species increase (P < 0.05), and 4-HPR cytotoxicity (P = 0.05; 4-HPR LC(99), 19.7 +/- 23.9 microm; range, 2.3-91.4). However, hypoxia affected 4-HPR + safingol cytotoxicity to a lesser extent (P = 0.04; 4-HPR LC(99), 4.9 +/- 2.3 microm; range, 2.0-8.2). Hypoxia increased AC RNA expression; the AC inhibitor NOE enhanced 4-HPR-induced ceramide species increase and cytotoxicity. The antioxidant N-acetyl-l-cysteine somewhat reduced 4-HPR cytotoxicity but did not affect ceramide species increase. We conclude the following: (a) 4-HPR was active against ESFT cell lines in vitro at concentrations achievable clinically, but activity was decreased in hypoxia; and (b) combining 4-HPR with ceramide modulators synergized 4-HPR cytotoxicity in normoxia and hypoxia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289350     DOI: 10.1158/0008-5472.CAN-04-0377

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.

Authors:  Aintzane Apraiz; Jolanta Idkowiak-Baldys; Naiara Nieto-Rementería; María Dolores Boyano; Yusuf A Hannun; Aintzane Asumendi
Journal:  Biochem Cell Biol       Date:  2012-03-19       Impact factor: 3.626

3.  Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamide.

Authors:  Nadine Darwiche; Ghada Abou-Lteif; Tarek Najdi; Lina Kozhaya; Ahmad Abou Tayoun; Ahmad Abou Tayyoun; Ali Bazarbachi; Ghassan S Dbaibo
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

4.  Mahanine, a novel mitochondrial complex-III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA damage response and regresses glioblastoma multiforme.

Authors:  Kaushik Bhattacharya; Arup K Bag; Rakshamani Tripathi; Suman K Samanta; Bikas C Pal; Chandrima Shaha; Chitra Mandal
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

5.  Induction of Mitochondrial Pathways and Endoplasmic Reticulum Stress for Increasing Apoptosis in Ectopic and Orthotopic Neuroblastoma Xenografts.

Authors:  Surajit Karmakar; Subhasree Roy Choudhury; Naren L Banik; Swapan K Ray
Journal:  J Cancer Ther       Date:  2011-06

6.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

Review 7.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 8.  Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate.

Authors:  Cungui Mao; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2008-06-13

9.  Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Authors:  Barry J Maurer; Min H Kang; Judith G Villablanca; Jitka Janeba; Susan Groshen; Katherine K Matthay; Paul M Sondel; John M Maris; Hollie A Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Beth Hasenauer; C Patrick Reynolds; Araz Marachelian
Journal:  Pediatr Blood Cancer       Date:  2013-06-29       Impact factor: 3.167

Review 10.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.